IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0150569.html
   My bibliography  Save this article

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin

Author

Listed:
  • Tarik Asselah
  • Alex J Thompson
  • Robert Flisiak
  • Manuel Romero-Gomez
  • Diethelm Messinger
  • Georgios Bakalos
  • Mitchell L Shiffman

Abstract

Background: Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the European Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult genotype to eradicate and PegIFN/RBV remains an effective option. The goal of this study was to devise a simple predictive score to identify GT3 patients with a high probability of achieving a sustained virologic response (SVR) with PegIFN alfa-2a/RBV therapy. Methods: Relationships between baseline characteristics and SVR were explored by multiple logistic regression models and used to develop a simple scoring system to predict SVR using data from 1239 treatment-naive GT3 patients who received PegIFN alfa-2a/RBV for 24 weeks in two large observational cohort studies. Results: The score was validated using a database of 473 patients. Scores were assigned for six factors as follows: age (years) (≤40: 2 points; >40 but ≤55: 1); bodyweight (kg) ( 200: 2; ≥100 but

Suggested Citation

  • Tarik Asselah & Alex J Thompson & Robert Flisiak & Manuel Romero-Gomez & Diethelm Messinger & Georgios Bakalos & Mitchell L Shiffman, 2016. "A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-20, March.
    • Handle: RePEc:plo:pone00:0150569
    DOI: 10.1371/journal.pone.0150569
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0150569
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0150569&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0150569?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Dongliang Ge & Jacques Fellay & Alexander J. Thompson & Jason S. Simon & Kevin V. Shianna & Thomas J. Urban & Erin L. Heinzen & Ping Qiu & Arthur H. Bertelsen & Andrew J. Muir & Mark Sulkowski & John , 2009. "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance," Nature, Nature, vol. 461(7262), pages 399-401, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Sean A. P. Clouston & Marcie S. Rubin & Jo C. Phelan & Bruce G. Link, 2016. "A Social History of Disease: Contextualizing the Rise and Fall of Social Inequalities in Cause-Specific Mortality," Demography, Springer;Population Association of America (PAA), vol. 53(5), pages 1631-1656, October.
    2. Chun-Yen Lin & Ji-Yih Chen & Tsung-Nan Lin & Wen-Juei Jeng & Chien-Hao Huang & Chang-Wen Huang & Su-Wei Chang & I-Shyan Sheen, 2011. "IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic Response in Patients with Hepatitis C Virus Genotype-1 Infection," PLOS ONE, Public Library of Science, vol. 6(3), pages 1-9, March.
    3. Thomas R O'Brien & James E Everhart & Timothy R Morgan & Anna S Lok & Raymond T Chung & Yongwu Shao & Mitchell L Shiffman & Myhanh Dotrang & John J Sninsky & Herbert L Bonkovsky & Ruth M Pfeiffer & an, 2011. "An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C," PLOS ONE, Public Library of Science, vol. 6(7), pages 1-9, July.
    4. Ming-Lung Yu & Chen-Hua Liu & Chung-Feng Huang & Tai-Chung Tseng & Jee-Fu Huang & Chia-Yen Dai & Zu-Yau Lin & Shinn-Cherng Chen & Liang-Yen Wang & Suh-Hang Hank Juo & Wan-Long Chuang & Jia-Horng Kao, 2012. "Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin," PLOS ONE, Public Library of Science, vol. 7(12), pages 1-8, December.
    5. Verónica Saludes & Elisabet Bascuñana & Elena Jordana-Lluch & Sònia Casanovas & Mercè Ardèvol & Esther Soler & Ramón Planas & Vicente Ausina & Elisa Martró, 2013. "Relevance of Baseline Viral Genetic Heterogeneity and Host Factors for Treatment Outcome Prediction in Hepatitis C Virus 1b-Infected Patients," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-8, August.
    6. Emilie Estrabaud & Kevin Appourchaux & Ivan Bièche & Fabrice Carrat & Martine Lapalus & Olivier Lada & Michelle Martinot-Peignoux & Nathalie Boyer & Patrick Marcellin & Michel Vidaud & Tarik Asselah, 2015. "IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-19, April.
    7. I-Cheng Lee & Yi-Hsiang Huang & Chien-Wei Su & Yuan-Jen Wang & Teh-Ia Huo & Kuei-Chuan Lee & Han-Chieh Lin, 2013. "CXCL9 Associated with Sustained Virological Response in Chronic Hepatitis B Patients Receiving Peginterferon Alfa-2a Therapy: A Pilot Study," PLOS ONE, Public Library of Science, vol. 8(10), pages 1-1, October.
    8. Eric R Londin & Margaret A Keller & Cathleen Maista & Gretchen Smith & Laura A Mamounas & Ran Zhang & Steven J Madore & Katrina Gwinn & Roderick A Corriveau, 2010. "CoAIMs: A Cost-Effective Panel of Ancestry Informative Markers for Determining Continental Origins," PLOS ONE, Public Library of Science, vol. 5(10), pages 1-12, October.
    9. Ester Aparicio & Mariona Parera & Sandra Franco & Nuria Pérez-Alvarez & Cristina Tural & Bonaventura Clotet & Miguel Angel Martínez, 2010. "IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients," PLOS ONE, Public Library of Science, vol. 5(10), pages 1-5, October.
    10. Helen Kovari & Stefan Russmann & Bruno Ledergerber & Daniel Müller & Margalida Rotger & Pablo Velli & Matthias Cavassini & Juan Ambrosioni & Andrea Bregenzer & Marcel Stöckle & Enos Bernasconi & Andri, 2015. "Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-11, July.
    11. Thanthima Suwanthawornkul & Thunyarat Anothaisintawee & Abhasnee Sobhonslidsuk & Ammarin Thakkinstian & Yot Teerawattananon, 2015. "Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis," PLOS ONE, Public Library of Science, vol. 10(12), pages 1-17, December.
    12. Deanna M. Santer & Daniel Li & Yanal Ghosheh & Muhammad Atif Zahoor & Dhanvi Prajapati & Bettina E. Hansen & D. Lorne J. Tyrrell & Jordan J. Feld & Adam J. Gehring, 2022. "Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    13. John M Murray & Rémy Moenne-Loccoz & Aurélie Velay & François Habersetzer & Michel Doffoël & Jean-Pierre Gut & Isabel Fofana & Mirjam B Zeisel & Françoise Stoll-Keller & Thomas F Baumert & Evelyne Sch, 2013. "Genotype 1 Hepatitis C Virus Envelope Features That Determine Antiviral Response Assessed through Optimal Covariance Networks," PLOS ONE, Public Library of Science, vol. 8(6), pages 1-9, June.
    14. Martin Probst & Christoph Hoeller & Peter Ferenci & Albert F Staettermayer & Sandra Beinhardt & Hubert Pehamberger & Harald Kittler & Katharina Grabmeier-Pfistershammer, 2014. "IL28B Polymorphism Cannot Predict Response to Interferon Alpha Treatment in Patients with Melanoma," PLOS ONE, Public Library of Science, vol. 9(11), pages 1-7, November.
    15. Verónica Saludes & Maria Alma Bracho & Oliver Valero & Mercè Ardèvol & Ramón Planas & Fernando González-Candelas & Vicente Ausina & Elisa Martró, 2010. "Baseline Prediction of Combination Therapy Outcome in Hepatitis C Virus 1b Infected Patients by Discriminant Analysis Using Viral and Host Factors," PLOS ONE, Public Library of Science, vol. 5(11), pages 1-8, November.
    16. Tonggang Liu & Kaihui Sha & Luhua Yang & Yun Wang & Liguo Zhang & Xianxian Liu & Fang Yang, 2014. "IL-28B Polymorphisms Correlated with Treatment Response in HCV-4 Mono-Infected Patients: A Meta-Analysis," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-10, March.
    17. Logan Dumitrescu & Cara L Carty & Kira Taylor & Fredrick R Schumacher & Lucia A Hindorff & José L Ambite & Garnet Anderson & Lyle G Best & Kristin Brown-Gentry & Petra Bůžková & Christopher S Carlson , 2011. "Genetic Determinants of Lipid Traits in Diverse Populations from the Population Architecture using Genomics and Epidemiology (PAGE) Study," PLOS Genetics, Public Library of Science, vol. 7(6), pages 1-15, June.
    18. Zhifang Jia & Yanhua Ding & Suyan Tian & Junqi Niu & Jing Jiang, 2012. "Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis," PLOS ONE, Public Library of Science, vol. 7(9), pages 1-10, September.
    19. Georgios Grammatikos & Christian Lange & Simone Susser & Susanne Schwendy & Nektarios Dikopoulos & Peter Buggisch & Jens Encke & Gerlinde Teuber & Tobias Goeser & Robert Thimme & Hartwig Klinker & Wul, 2014. "Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients," PLOS ONE, Public Library of Science, vol. 9(2), pages 1-9, February.
    20. Antonio Rivero-Juárez & Luis F Lopez-Cortes & Angela Camacho & Almudena Torres-Cornejo & Juan A Pineda & Manuel Marquez-Solero & Antonio Caruz & Rosa Ruiz-Valderas & Julian Torre-Cisneros & Alicia Gut, 2012. "Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients," PLOS ONE, Public Library of Science, vol. 7(11), pages 1-6, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0150569. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.